A Multiple Dose Study of Grazoprevir (MK-5172) in Hepatitis C-Infected Participants (MK-5172-010)
Status:
Completed
Trial end date:
2014-07-31
Target enrollment:
Participant gender:
Summary
The goal of this study was to compare hepatic pharmacokinetics (PK) derived from liver tissue
to plasma PK after administration of grazoprevir (MK-5172) to participants with chronic
hepatitis C virus (HCV) infection. Participants will be randomized to one of four different
liver ultrasound-guided Fine Needle Aspirate (FNA) schedules (at 4-, 8-, 24-, or 72-hours
after the Day 7 dose).